Company intelligence / Profile preview
Stainwei Biotech
Suzhou, Jiangsu, Chinastainwei.cn ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Stainwei Biotech has advanced monoclonal antibodies for oncology and ophthalmology, with its lead anti-VEGF mAb (hPV19) in Phase 2 for ocular indications and its PD-1 (hAB21) and other mAbs in ongoing Phase 1 and preclinical cancer trials; data show superior activity to current anti-VEGF and anti–PD-1 therapies in preclinical and early clinical studies.
- Therapeutic areas
- EndocrinologyNeurologyInfectious DiseasesOncologyOphthalmology
- Modalities
- Monoclonal antibodySmall molecule
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Beyond the preview
Go deeper on Stainwei Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Stainwei Biotech.